Imricor Medical Systems Inc (imr) Logo

Imricor Medical Systems Inc (IMR)

___:___ · Healthcare

IMR Chart


IMR's Principal Activity is the design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -45.01%
vs ASX 200 (1yr) -62.91%


Market Capitalisation
ASX Rank 745 of 2,316
Sector Rank 58 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies SOM / KZA / GSS
EPS -$0.168
DPS $0.00
NTA per share $0.25

Broker Consensus

IMR is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Imricor Medical Systems Inc (IMR) is a US based medical device company that seeks to address the current issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. The Company's primary product offering, the Vision-MR Ablation Catheter is specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Burnsville Minnesot USA 55337
Registry Computershare
Auditor Baker Tilly US, LLP
Date Listed 30 Aug 2019

Upcoming Calendar (Forecasted)

Date Event
24/02/2022 Report (Prelim)
19/04/2022 Report (Annual)
25/08/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Anita Messal Non-Executive Director Mar 2021 Director Bio icon

Ms Anita Messal

Non-Executive Director

Ms Messal has 35 years of experience in the healthcare sector and is currently the Chief Integration Officer at AccentCare,Inc. a US based national post-acute healthcare provider, where she is responsible for the integration of merged and acquired entities across all areas of the business. Prior to AccentCare, she most recently served as President & Chief Operating Officer of PlanSource. In this role, she was responsible for company technology & operations including all aspects of Technology, Product, Service Delivery, Legal, and Human Resources. Ms Messal has participated in fund raising from start-up through IPO and sale to strategic buyers and private equity. She has worked in both Fortune 100 and start-up companies with experience in public, private and non-profit businesses. Her experience includes working in domestic and international markets, where she involved in developing programs and partnerships in the United Kingdom and the European Union.

Mr Peter McGregor Non-Executive Director May 2019 Director Bio icon

Mr Peter McGregor

Non-Executive Director

Mr McGregor has over 30 years' experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. He is Chair of Risk Committee.

Mr Mark Tibbles Non-Executive Director Sep 2014 Director Bio icon

Mr Mark Tibbles

Non-Executive Director

Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently the Managing Director of Strategic Stage Ventures, LLC and an owner and managing member of STEM Fuse. Prior to his current roles, Mr Tibbles was an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also President and founder of PRC Consulting, Inc. from 1998 until 2013, when PRC was sold. Mr Tibbles currently serves as an independent director of, Inc. He is Member of Risk Committee.

Mr Steve Wedan Chief Executive Officer,President,Executive Chairman,Executive Director May 2006 Director Bio icon

Mr Steve Wedan

Chief Executive Officer,President,Executive Chairman,Executive Director

Mr Wedan is in charge for the overall management and strategic direction of the Company. Mr Wedan has over 29 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of range of international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the boards of Medical Device Research Forum and Water Rescue Innovations, Inc.

Mr Kobe Li Company Secretary N/A
Lori Milbrandt Chief Financial Officer N/A
Gregg Stenzel Chief Operating Officer N/A
Nick Twohy Executive Director of Marketing N/A
Greg Englehardt Executive Director of Sales N/A
Tom Lloyd Vice President of Clinical Research N/A
Dan Sunnarborg Vice President of Engineering N/A
Jennifer Weisz Vice President of Regulatory and Quality N/A

Director Transactions

IMR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/05/21 Steve Wedan Issued 304,254 $2.00 $608,508 Issue of options
07/05/21 Mark Tibbles Issued 40,896 $2.00 $81,792 Issue of options
07/05/21 Peter McGregor Issued 40,896 $2.00 $81,792 Issue of options
07/05/21 Anita Messal Issued 38,340 $2.00 $76,680 Issue of options
14/05/20 Steve Wedan Issued 579,187 $1.34 $776,110 Issue of options
14/05/20 Mark Tibbles Issued 71,010 $1.34 $95,153 Issue of options
14/05/20 Doris Engibous Issued 66,571 $1.34 $89,205 Issue of options
14/05/20 Peter McGregor Issued 71,010 $1.34 $95,153 Issue of options
31/12/19 Steve Wedan Transfer 2,518,219 $1.195 $3,009,272 Off-market transfer
31/12/19 Steve Wedan Transfer 2,518,219 $1.195 $3,009,272 Off-market transfer
31/12/19 Mark Tibbles Issued 2,897 $1.195 $3,462 Conversion of convertible notes
31/12/19 Steve Wedan Issued 501 $1.195 $599 Conversion of convertible notes
24/12/19 Mark Tibbles Buy +30,000 $0.341 $10,230 Exercise of options
24/12/19 Mark Tibbles Exercise 30,000 $0.341 $10,230 Exercise of options

Director Interests

The current holdings of IMR directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Anita Messal 07/05/2021 0 N/A 38,340 N/A
Mark Tibbles 07/05/2021 4,581,878 N/A 526,806 N/A
Steve Wedan 07/05/2021 0 4,424,733 2,144,241 N/A
Peter McGregor 07/05/2021 N/A N/A 246,906 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Dec 31, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
No Top 20 Shareholder Information 0 0.00%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 191 189 87 256 148 871

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Warren G Herreid II and KAHR Foundation 18/03/2021 10,771,092 8.57
Siemens Medical Solutions USA Inc 18/03/2021 8,384,150 6.67
One Funds Management Ltd 10/09/2021 7,180,000 5.05
Regal Funds Management Pty Limited 14/09/2021 8,311,716 5.84
BlackRock Investment Management Australia 20/09/2021 15,448,252 10.86

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
20-09-21 BlackRock Investment Management Australia 7,596,885 6.98 10.86
14-09-21 Regal Funds Management Pty Limited 8,311,716 -- 5.84
10-09-21 One Funds Management Ltd 7,180,000 -- 5.05
18-12-20 Warren G Herreid II and KAHR Foundation 273,972 10.02 8.59

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $1.49 30 June
Page Icon
IMR Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.